



CTMCT Pulse

Center for Research in Transfusion Medicine and Cell Therapies
Highlights from the CTMCT Community – Sharing Research and Innovation

Top News

The Economics of Prehospital
Blood Conference

Innovation &
Commercialization Council
and Scientific Advisory Board

SAB Spotlights

CTMCT Seminars

Notable Member News and
Publications



Spring 2026

Dear CTMCT Members

The second edition and exciting things to come

Dear CTMCT Members,

We are delighted to share the Spring issue of our newsletter. As mentioned previously, we plan to publish this newsletter seasonally to highlight CTMCT news, faculty spotlights, new projects, pilot award updates, and progress across our community. Please feel free to send us any news or accomplishments you would like us to showcase.

We are also eager to welcome new members from multidisciplinary backgrounds, so we encourage you to spread the word about the Center. We hope you have been enjoying our monthly seminar series, which highlights the outstanding talent within CTMCT. Be sure to mark your calendars for upcoming talks, and please let me know if you are interested in presenting.

In this issue, we spotlight members of our newly formed Scientific Advisory Board (SAB) as well as our Innovation & Commercialization Council (ICC). These groups are composed of leaders in the field who are committed to supporting our members in advancing their careers and research goals.



We are pleased to announce a third round of pilot awards this fall and encourage you to consider applying. These awards are designed to foster multidisciplinary collaborations and generate preliminary data to support future grants, publications, and sustained research partnerships. This year, thanks to the support of Dr. Julie Ann Sosa (Chair, Department of Surgery) and Dr. Sandy Feng (Vice Chair of Research, Department of Surgery), additional funding will be available for pilot grants.

Looking ahead, we plan to reschedule our retreat for the fall. Please also save the date for the CTMCT Conference—CTTACC (Cell Therapies in Trauma and Critical Care Medicine)—which is currently being planned for May 2–5, 2027, in Scottsdale, Arizona. If you have ideas for talks or sessions, we would love to hear from you.

Finally, we encourage CTMCT members to submit collaborative grants through CTMCT and the Department of Laboratory Medicine. We now offer a streamlined submission process with administrative support, graphic design assistance, and grant writing services. Several groups have already submitted proposals, including a successful Department of Defense (DoD) award (see details below). Please feel free to reach out to Dr. Shibani Pati or Mr. Tony Hang, Chief Administrative Officer for CTMCT, for more information.

Thank you for your continued support. We look forward to another exciting and productive year ahead.

My very best wishes,
Shibani Pati MD PhD
Director Center for Research in Transfusion Medicine and Cellular Therapies

The Economics of Prehospital Blood Conference

On April 23-24, CTMCT is co-hosting The Economics of Pre-hospital Blood meeting to be held at the American College of Surgeons Building in Washington DC. The goal is to promote advocacy for the use of pre-hospital blood on ambulances and medical transport where many patients bleed to death. Today, only 275 of 11,400 eligible ground ambulances carry blood products, but with nationwide collaboration, that number is doubling every year. Join us in accelerating this lifesaving effort. For more information go to <https://phblood.com/>

April 23-24, 2026

American College of Surgeons Building
20 F St NW, Washington, DC 20001
<https://phblood.com/>

Introducing our CTMCT Advisory Boards

In this issue, we're excited to spotlight members of our Scientific Advisory Board and share the journeys that have shaped their careers in cell therapies and transfusion medicine. The Scientific Advisory Board (SAB) and Innovation & Commercialization Council (ICC) bring together leaders from biotechnology, academia, government, and defense to provide strategic guidance in cell therapies and transfusion medicine. Below is the current roster of members:

Innovation & Commercialization Council

Andre Cap, MD, PhD — CSO, Velico Inc.

Becky Cap — Senior Vice President of Biotherapies, Vitalant

Donna Chang — CEO, Hope Biosciences

Mike Fitzpatrick, PhD — CSO, Cellphire Inc.

Adam Gerber, MD, PhD — Medical Director, Octapharma USA

Obi Greenman — CEO, Cerus Corp.

Brett Janis, PhD — CEO, DesiCorp Inc.

Jessica Kenyon — CEO, The Conafay Group

Vijayan Nair, PhD — Senior Director, Special Projects, Octapharma USA

Lauren Palestrini, PhD, CFA — CSO, Medical Technology

Enterprise Consortium (MTEC) / DoD

Zachary Rapp, MA — CEO, Sigma Genetics

Taryn Rose, MD — DARPA Consultant

Introducing our CTMCT Advisory Boards (Continued)

Scientific Advisory Board

Victor Baum, MD — FDA (Ret), Former Lead Physician, Division of Blood Components and Devices, CBER, FDA

Kenneth Bertram, MD, PhD, COL US Army (Ret) — COO, AFIRM; Adjunct Professor, Lab Medicine, UCSF; Director, CTMCT SAB

Greg Bonfiglio — Managing Partner, Proteus LLC

Michael Busch, MD, PhD — Professor of Lab Medicine, UCSF; Director Emeritus, Vitalant Research Institute

Charles S. Cox Jr., MD — Professor of Pediatric Surgery; Director, Pediatric Program in Regenerative Medicine, UT Houston

John Holcomb, MD, COL US Army (Ret) — Professor of Surgery, University of Alabama

Clifford Lowell, MD, PhD — Professor of Lab Medicine, UCSF

Lester Martinez Lopez, MD — General, US Army (Ret); Former Assistant Secretary of Defense for Health

Chris Mason, MD, PhD, FRSB, FRCS, FMedSci — Professor of Cell and Gene Therapy, University College London

Jan Nolta, PhD — Professor and Director, Stem Cell and Gene Therapy Program, UC Davis

Philip Norris, MD — Professor of Lab Medicine, UCSF; Vitalant Research Institute

Beth Shaz, MD — Professor and Director, Marcus Center for Cellular Cures, Duke University

Phil Vanek — CTO, Gamma Biosciences; ISCT Chief Commercialization Officer

Pampee Young, MD, PhD — Medical Director, American Red Cross

CTMCT Scientific Advisory Board Spotlight

Biography

From my perspective working at the intersection of biotechnology and translational medicine, one of the most important factors in bringing new therapies to patients is the collaboration between academic science and the investment community. Many transformative ideas originate in university laboratories including those at University of California San Francisco and the Center for Transfusion Medicine and Cellular Therapies (CTMCT)—but translating those discoveries into real therapies requires significant capital, specialized expertise, and long-term commitment.

Developing a new biologic or cellular therapy can take more than a decade and hundreds of millions of dollars. Venture investors and strategic partners help provide the resources needed to advance discoveries through manufacturing development, clinical trials, and regulatory approval. Just as importantly, experienced investors often help assemble leadership teams, build companies around promising technologies, and connect academic discoveries with the broader healthcare ecosystem.

A powerful example from UCSF is Rilzabrutinib, an innovative therapy for autoimmune disease that originated from research at UCSF and was advanced by Principia Therapeutics with strong support from the investment community. The company's success and its eventual acquisition by Sanofi for \$3.7B demonstrates how academic discovery, entrepreneurial leadership, and venture investment can work together to transform scientific insight into medicines that reach patients.

For researchers working in transfusion medicine and cellular therapies, understanding how the investment ecosystem operates can help ensure that promising discoveries move beyond the laboratory and ultimately benefit patients.

Greg Bonfiglio

Managing Partner Proteus LLC




CTMCT Scientific Advisory Board Spotlight

Biography

John Bradley Holcomb received his M.D. from the University of Arkansas Medical School in 1985, entered the U.S. Army, and completed his general surgery training in 1991. Dr Holcomb then deployed with the Joint Special Operations Command for the next decade. He led one of the first Military Civilian Partnerships from 1999–2001 at Ben Taub in Houston Texas. From 2002 to 2008, COL Holcomb was the Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant for the Army Surgeon General. In that capacity he helped establish the Joint Trauma System and had multiple combat deployments. He is a three-time recipient of the Army's Greatest Invention award, the 'A' Designator in Military Medicine, the Order of Military Medical Merit and the Department of the Army Research and Development Achievement Award for Leadership Excellence. COL Holcomb retired from active duty in 2008 and received the Lifetime Achievement Award in Trauma Resuscitation Science from the American Heart Association, the United States Special Operations Command Medal and the Service award from the American College of Surgery. He was a member of the Committee on Tactical Combat

John B. Holcomb MD, FACS

US Army (Ret), Professor of Surgery, Univ. Alabama



Casualty Care from 2001–2025 and has been an active member of the Committee on Surgical Combat Casualty Care since 2012. From 2008–2019 Dr. Holcomb worked at UT Health, Houston Tx as a Professor of Surgery and the founding Chief of the Division of Acute Care Surgery, where he received more than 60 million dollars in federal research funding. In 2016 he received the MAJ Jonathan Letterman award from the National Museum of Civil War Medicine. In 2019 Dr Holcomb joined the University of Alabama at Birmingham AL as a Professor of Surgery. In 2022 he was awarded the Robert Danis Prize from International Surgical Society and in 2025 the United States Special Operations Command Medical Hall of Honor. Over the last 5 years he has helped lead the implementation of prehospital blood programs in the US (<https://prehospitaltransfusion.org>) and since 2022 has been volunteered in Ukraine 5 times. Dr. Holcomb is actively involved in clinical medicine, education, research and entrepreneurship. He reviews papers for 51 journals, has published > 800 peer reviewed articles, consults with several companies and serves on multiple boards. Dr. Holcomb and his wife, Dr. Kelly Wirfel were married in 1998 and have 2 adult children.

CTMCT Scientific Advisory Board Spotlight

Biography

Vic Baum trained in pediatrics at UCSF and the MGH. He returned to UCSF as Chief Resident and then a pediatric cardiology fellow. While director of a pediatric ICU he also did an anesthesiology residency. He spent his academic career at UCLA doing cardiac anesthesia and pediatric critical care, and then UVA also doing cardiac anesthesia and pediatric critical care, as chief of cardiac anesthesia, executive vice-chair, F.A. Berry Professor of Pediatric Anesthesia and Professor of Pediatrics. He co-authored a book on anesthesia and genetic and metabolic syndromes, currently in preparation for a fourth edition. He worked with an organization doing pediatric cardiac surgery overseas and developed an affinity for Central Asia. In years past he served as a consultant to the Asian Development Bank and the Ministry of Health of Uzbekistan. He retired from UVA and spent over a decade at the FDA in the Office of Blood Research and Review. His group's interest was blood and transfusion in general, with a special interest in modified blood products, such as hemoglobin-based oxygen carriers and dried or otherwise modified blood components. He also served on FDA's Pediatric Review Committee reviewing "everything pediatric". He maintains an adjunct appointment at GW. He lives in Charlottesville, VA.

Victor Baum, M.D.

F.A. Berry Professor of Pediatric Anesthesiology and Professor of Pediatrics, University of Virginia (retired); U.S. FDA (retired); Adjunct Professor, George Washington University School of Medicine



Launch of the Center for Precision Research in Critical Care



We would like to highlight a new center launched by our colleagues Dr. Carolyn Calfee and Dr. Michael Matthay, both members of the Center for Transfusion Medicine and Cell Therapies (CTMCT). Their newly established UCSF Center for Precision Research in Critical Care (CPRCC) complements CTMCT's mission by advancing translational research and clinical innovation in critical care.

The CPRCC focuses on mentorship for early-stage physician-scientists, pilot grants for translational critical care research, and support in computational biology, database design and management, and biospecimen banking. The Center will sponsor seminars every other month and aims to integrate critical care research across UCSF divisions and departments, including UCSF Parnassus, ZSFG, and UCSF Children's Hospital. Initial support has been provided by the Departments of Medicine, Anesthesiology, Pediatrics, and Surgery, as well as the UCSF Nina Ireland Lung Program.

More details are available at cprcc.ucsf.edu.



CTMCT Seminars

Our 2026 and 2027 CTMCT Seminars will feature inspiring talks from experts across UCSF and beyond. Each session offers a chance to learn about the latest advances in transfusion medicine, cell therapies, and cutting-edge biomedical research.

Month	Time	Location	Speaker
April 15, 2026	1pm – 2pm	HSE720, Parnassus	Dr. Gabriela Fragiadakis
May 20, 2026	1pm - 2pm	HSE720, Parnassus	Dr. Alexis Combes
September 16, 2026	1pm – 2pm	HSE720, Parnassus	Dr. Shibani Pati
October 21, 2026	1pm - 2pm	HSE720, Parnassus	Dr. Ari Molofsky
November 18, 2026	1pm – 2pm	HSE720, Parnassus	Dr. Michael P. Busch
December 16, 2026	1pm - 2pm	HSE720, Parnassus	Dr. Carolyn Calfee
January 20, 2027	1pm – 2pm	HSE720, Parnassus	Dr. Christopher Dvorak
February 17, 2027	1pm - 2pm	HSE720, Parnassus	TBD
March 17, 2027	1pm – 2pm	HSE720, Parnassus	Dr. Kelsey Collins
April 21, 2027	1pm - 2pm	HSE720, Parnassus	TBD



Member News, Awards & Publications



American Diabetes Association Pathway to Stop Diabetes Award for Dr. Sagar Bapat

Congratulations to Sagar Bapat on receiving this grant and award. His research focuses on developing a novel T cell based “living therapeutic” to enhance thermogenic function in adipose tissue. By combining targeted cellular therapy with CRISPR technology, his team aims to create durable, preventative treatments for obesity-induced diabetes. The award will support efforts to translate this approach into long-term therapies that restore metabolic health and improve insulin sensitivity.



Dr. Shibani Pati and Dr. Clifford Lowell Awarded 3 million-dollar DoD Grant for Dried Platelet Biologic in Trauma Care

Shibani Pati, PhD, and Clifford Lowell, MD, PhD, have received a Department of Defense (DoD) award (BA240278) for their project, “Development of a Dried Platelet-Derived Biologic (FPH) for the Acute and Prolonged Casualty Care of Patients With Polytrauma and TBI.” The project supports development of a freeze-dried platelet hemostatic product designed to reduce intracranial hemorrhage and repair blood-brain barrier damage following traumatic brain injury. The stable, lyophilized product could provide a deployable solution for trauma care in remote and prolonged casualty settings.



Emily’s Entourage Grant Award Supports Synthetic Receptor Engineering for Cystic Fibrosis

Co-PI Kyle Cromer, PhD, Department of Surgery, UCSF, and Co-PI Sriram Vaidyanathan, PhD, Department of Pediatrics, Nationwide Children's Hospital, have been awarded a 2025 Emily’s Entourage Translational Grant to support their project, Engineering synthetic receptors to selectively enrich CFTR-corrected airway basal cells. This two-year award (\$100,000 in total direct costs) will enable the development of synthetic receptor platforms designed to selectively identify and enrich gene-corrected airway basal stem cells. The goal is to enhance the efficiency, purity, and regenerative capacity of corrected cell populations, advancing the translational potential of cell-based therapies for cystic fibrosis.

Congratulations to Dr. Cromer and Dr. Vaidyanathan!



Member News, Awards & Publications (Continued)



Dr. Emily Kelly Awarded NHLBI StARR Grant for Next-Generation Syphilis Screening

Emily Kelly, MD, MSc, has been awarded a competitive StARR grant from the National Heart, Lung, and Blood Institute (NHLBI) for her project, “Proteome-Wide Epitope Discovery for the Development of Next-Generation Syphilis Screening of Blood Donors.” Her research aims to improve blood donor screening by identifying highly accurate protein epitopes from *Treponema pallidum*, the bacterium that causes syphilis. Her mentors for this project include Jeffrey Whitman, Mike Busch, and Joe DeRisi.



New Funded Award for Drs. Lucy Kornblith and Roland Bainton

Congratulations to Drs. Kornblith and Bainton for being awarded a \$1.2 million NIH CLEAR research grant to support the Platelet Molecular Endotypes of Thromboinflammation and Treatment Response in COVID-19 (P-METTRIC) Study. This project investigates platelet-driven thromboinflammation and identifies molecular endotypes associated with differential treatment response and clinical outcomes. The work aims to advance mechanistic understanding of viral-associated coagulopathy and inform precision treatment strategies for COVID-19 and related disease.



Dr. Natalie Escobar Awarded American Heart Association Postdoctoral Fellowship for her work with Dr. Lucy Kornblith

General Surgery Resident Dr. Escobar was awarded a two-year American Heart Association Postdoctoral Fellowship totaling \$155,284 to support her project, “The Role of P-selectin in the Development of Venous Thromboembolism in Injured Patients.” Her research examines molecular mechanisms underlying post-injury thrombosis and aims to identify pathways that may serve as therapeutic targets. This award reflects both the strength of her scholarship and the translational impact of platelet biology research underway in Dr. Kornblith’s lab.

Congratulations to Dr. Escobar and the Kornblith Lab on this major achievement!



Medical Technology Enterprise Consortium 10th Annual Meeting & 10-Year Celebration

MTEC will host its 10th Annual Membership Meeting and 10-Year Celebration on June 16–17, 2026, in Washington, DC. Led by Dr. Lauren Palestrini, Chief Science Officer, the event will convene leaders from industry, government, and academia to address emerging military medical needs and future capability gaps. The meeting fosters cross-sector collaboration and partnership across the defense medical innovation ecosystem.

Learn more: <https://mtec-sc.org/events/annual-membership-meeting>

Member News, Awards & Publications (Continued)



Targeted β -catenin-Ikaros Therapeutic Strategy Published in Nature Cancer

Dr. Hilde Schjerven and Dr. Markus Muschen and colleagues described targeted engagement of β -catenin Ikaros complexes in refractory B-cell malignancies. Published in Nature Cancer, the study uncovers a novel therapeutic vulnerability with significant implications for precision oncology and treatment-resistant disease.

<https://pubmed.ncbi.nlm.nih.gov/41507538/>



Plasma Chondroitin Sulfate Predicts Fluid Resuscitation Response in Sepsis

Dr. Eric P. Schmidt, **Dr. Michael A. Matthay**, and colleagues identified plasma chondroitin sulfate as a biomarker predicting the effectiveness of fluid resuscitation strategies in patients with sepsis. The study links endothelial glycocalyx biology to clinical response, offering a potential precision-guided approach to fluid management in critical illness.

<https://pubmed.ncbi.nlm.nih.gov/41632536/>



New Co-Authored Study by Drs. Kornblith and Bainton

Dr. Lucy Zumwinkle Kornblith (Surgery & Lab Med/UCSF) and Dr. Roland Bainton (Anesthesia/UCSF) co-authored a study defining platelet molecular maturation, a transcriptomic model linking platelet aging with the storage lesion. Using RNA sequencing, the team showed aging follows a coordinated molecular trajectory, while cold storage preserves features that improve platelet function and transfusion outcomes.

<https://pubmed.ncbi.nlm.nih.gov/41676597/>



Multiomic ARDS & Sepsis Mortality Study Published in Journal of Clinical Investigation

Dr. Carolyn Calfee, **Dr. Michael Matthay**, and collaborators reported longitudinal multiomic signatures of ARDS and sepsis inflammatory phenotypes associated with mortality. By integrating multiomic profiling, the study identifies biologic pathways linked to outcomes, helping refine precision medicine strategies in critical illness.

<https://pubmed.ncbi.nlm.nih.gov/41329523/>



Member News, Awards & Publications (Continued)



New Study Published in Blood by the Shibani Pati and Alpa Trivedi entitled “A Dried Platelet-Derived Biologic for Blood-Brain Barrier Repair and Hemorrhage Control Following TBI in Mice”.

Traumatic Brain Injury (TBI) is the leading cause of death in children and adults aged 18–44. Despite its high prevalence and devastating consequences, there are currently few effective therapies that target the acute, life-threatening complications of TBI – particularly cerebral edema and intracranial hemorrhage (ICH). Our findings demonstrate, for the first time, that a dried, first in class, platelet-derived biologic can promote vascular repair and neuroprotection in TBI.

<https://pubmed.ncbi.nlm.nih.gov/41843452/>



Recent Publications by CTMCT Members

- ◆ Beyond transfusion: Platelet derived therapeutic products as a new frontier for blood establishments and transfusion medicine

Burnouf T, Strengers P, **Busch MP**.

Vox Sang. 2026 Feb;121(2):114–123. doi:10.1111/vox.70155. Epub 2025 Nov 24. PMID: 41285440.

<https://pubmed.ncbi.nlm.nih.gov/41285440/>

- ◆ Utility of Animal Models of Pneumonia and Sepsis

Taenaka H, Maishan M, Watanabe R, **Matthay MA**.

Clin Chest Med. 2026 Mar;47(1):105–117. doi:10.1016/j.ccm.2025.11.005. Epub 2025 Dec 22.

PMID: 41651592

<https://pubmed.ncbi.nlm.nih.gov/41651592/>

- ◆ Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients.

Smith AL, Denny N, Chahrour C, Sharp K, Arachi M, Dopico-Fernandez AM, Elliott N, Harman JR, Jackson T, **Geng H**, Smith O, Bond J, Roberts I, Stam RW, Crump NT, Davies JOJ, Roy A, Milne TA.

Blood. 2025 Oct 23; 146(17):2073–2087.

<https://pubmed.ncbi.nlm.nih.gov/40729681/>

- ◆ Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia.

Lee J, Sun R, Kume K, Robinson ME, Cheng Z, Cosgun KN, Ma N, Hurtz C, **Geng H**, Luger SM, Litzow MR, Paietta E, Chen J, Vaidehi N, Müschen M.

Science Signaling. 2026 Feb 10; 19(924):eadw5054.

<https://pubmed.ncbi.nlm.nih.gov/41666265/>

Recent Publications by CTMCT Members (continued)

- ◆ An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibition.

Wang X, DeFilippis RA, **Geng H**, Shah NP, Li HY.
Bioorganic Chemistry. 2026 Feb 03; 173:109601.
<https://pubmed.ncbi.nlm.nih.gov/41671740/>

- ◆ Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.

Izgutdina A, Rashid T, Temple WC, Aminov S, Patiño-Escobar B, Walunj S, **Geng H**, Takamatsu H, Gil-Alós D, Kang AS, Ramos E, Chen SY, Johnson H, Nix MA, Naik A, Li M, Yuan CM, Wang HW, Sahu S, Larson RC, Carpenter C, Salangsang F, Phojanakong P, Serrano JAC, Tariq I, Zakraoui O, Steri V, Valeri A, **Martinez-Lopez J**, Maus MV, Parekh S, Verma A, Shah NN, **Wiita AP**.
Journal for ImmunoTherapy of Cancer. 2025 Dec 30; 13(12).
<https://pubmed.ncbi.nlm.nih.gov/40463123/>

- ◆ Plasma constituents promote endothelial thromboinflammatory dysfunction after hemorrhagic shock

Sanders KE, Pokharel MD, Osborn BK, Wang YW, Wade CE, **Kornblith LZ**, Cohen MJ, Cardenas JC.
Shock. 2026. doi:10.1097/SHK.0000000000002816. PMID: 41735192.

<https://pubmed.ncbi.nlm.nih.gov/41735192/>

- ◆ Organ Crosstalk During Injury: Mechanisms of Lung-Kidney Interaction in Critical Illness.

Sullivan KM, Liu KD, **Matthay MA**. Compr Physiol. 2025 Dec;15(6):e70069. doi: 10.1002/cph4.70069. PMID: 41340336 Free PMC article. Review.
<https://pubmed.ncbi.nlm.nih.gov/41340336/>

- ◆ IKAROS Gene Regulatory Network Reveal ERG as a Vulnerability in B-cell Acute Lymphoblastic Leukemia

Paculova H, Richman A, Boyd J, Bernil JC, Rodriguez P, Ayongaba E, Ghule P, Drivet E, Palaria A, Dajani M, Verhoeven E, Saviola A, Stein GS, **Schjerven H**, Fietze S.

bioRxiv [Preprint]. 2025 Dec 29:2025.12.29.696402. doi:10.64898/2025.12.29.696402. PMID: 41509392.
<https://pubmed.ncbi.nlm.nih.gov/41509392/>

- ◆ Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells.

Kasap C, Izgutdina A, Patiño-Escobar B, Kang AS, Chilakapati N, Akagi N, Manoj A, Johnson H, Rashid T, Werner J, Barpanda A, **Geng H**, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Aleman A, Wicaksono G, Kelii KMK, Dalal R, Ramos E, Vijayanarayanan A, Lakhani K, Salangsang F, Phojanakong P, Camara Serrano JA, Zakraoui O, Tariq I, Chari A, Chung A, Kumar AD, Martin TG, Wolf J, Wong SW, Steri V, Shanmugam M, Boise LH, Kortemme T, Parekh S, Stieglitz E, Licht JD, Karlon WJ, Barwick BG, **Wiita AP**.
Blood. 2025 Aug 14; 146(7):819-833.

Contacts and Leadership

Director

Shibani Pati, MD, PhD — Director
Shibani.Pati@ucsf.edu

Program Leads

Lucy Kornblith, MD — Trauma and Transfusion Medicine
Lucy.Kornblith@ucsf.edu

Arun Wiita, MD, PhD — Oncology
Arun.Wiita@ucsf.edu

Emin Maltepe, MD, PhD — Pediatrics and Neonatology
Emin.Maltepe@ucsf.edu

Brian Shy, MD, PhD — Cell Therapy Production
Brian.Shy@ucsf.edu

Michael Matthay, MD — Cell Therapies in Critical Care
Michael.Matthay@ucsf.edu

Anthony Luke, MD — Orthopedics
Anthony.Luke@ucsf.edu

Philip Norris, MD — Transfusion Medicine and Vitalant Blood Bank
Philip.Norris@ucsf.edu

Hilde Schjerven, PhD — Immunology
Hilde.Schjerven@ucsf.edu

Education Director

Elena Nedelcu, MD — Education Director
Elena.Nedelcu@ucsf.edu

Scientific Program Director

Alpa Mahuvakar, PhD — Scientific Program Director
alpa.mahuvakar@ucsf.edu

Chief Administrative Officer

Tony Hang — Chief Administrative Officer ✉ Tony.Hang@ucsf.edu

Administrative Support

Jonathan Ho - Jonathan.Ho2@ucsf.edu

Courtney Wong - courtney.wong3@ucsf.edu

Vicky Ren - Vicky.Ren@ucsf.edu